HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genelabs Technologies Inc.

Division of GlaxoSmithKline PLC
www.genelabs.com

Latest From Genelabs Technologies Inc.

GSK Tries to Mimic Real-World Biotech

Not satisfied with its R&D experiments to date, GSK has taken its most radical step yet toward re-creating biotech within its walls: even smaller units complete with investment boards occupied by external VCs and CEOs and milestone-based funding and external VCs.
Business Strategies Research and Development Strategies

Watson's Strategy for Beating the Big Boys

Watson's launch of incontinence drug Oxytrol illustrates the opportunities and challenges specialty pharma companies face when they try to move into primary care markets dominated by Big Pharma. Watson's added a whole set of Big Pharma-experienced managers and is betting that their expertise can guide it through the intimidating process of selecting and launching products. Even so, launching a product into primary care markets requires a commitment that stresses resources and changes the corporate culture.
BioPharmaceutical

A Precarious Union: Combining Proprietary and Generic Businesses

The major generics companies, flush with cash from the recent plethora of patent expirations, are all forging ahead in the proprietary business in order to boost margins and even out the volatile revenues and earnings inherent in their core business. They're pursuing, by and large, strategies that don't take them far from their core expertise and involve reformulating known compounds. Some companies have had moderate success, but weaving together two such disparate businesses is a challenge.
BioPharmaceutical Strategy

Asian AIDS Markets: Growing Opportunities

With the world' s second largest concentration of HIV patients (after Africa), Southeast Asia is a booming market for AIDS products. Government initiatives to prevent and combat the spread of this virus present opportunities for Western companies in both diagnostic and therapeutic products.
BioPharmaceutical Medical Device
See All

Company Information

UsernamePublicRestriction

Register